Cargando…
Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease
OBJECTIVE: Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors predictive of a deterioration in phenotype (‘transition’) in patients initially presenting with non-severe d...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326262/ https://www.ncbi.nlm.nih.gov/pubmed/32601172 http://dx.doi.org/10.1136/lupus-2020-000394 |
_version_ | 1783552314408173568 |
---|---|
author | Nikolopoulos, Dionysis S Kostopoulou, Myrto Pieta, Antigoni Flouda, Sofia Chavatza, Katerina Banos, Aggelos Boletis, John Katsimbri, Pelagia Boumpas, Dimitrios T Fanouriakis, Antonis |
author_facet | Nikolopoulos, Dionysis S Kostopoulou, Myrto Pieta, Antigoni Flouda, Sofia Chavatza, Katerina Banos, Aggelos Boletis, John Katsimbri, Pelagia Boumpas, Dimitrios T Fanouriakis, Antonis |
author_sort | Nikolopoulos, Dionysis S |
collection | PubMed |
description | OBJECTIVE: Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors predictive of a deterioration in phenotype (‘transition’) in patients initially presenting with non-severe disease. METHODS: Patients from the ‘Attikon’ cohort with disease duration ≥1 year were included. Disease at diagnosis was categorised as mild, moderate or severe, based on the British Isles Lupus Assessment Group manifestations and physician judgement. ‘Transition’ in severity was defined as an increase in category of severity at any time from diagnosis to last follow-up. Multivariable logistic regression was performed to identify baseline factors associated with this transition. RESULTS: 462 patients were followed for a median (IQR) of 36 (120) months. At diagnosis, more than half (56.5%) had a mild phenotype. During disease course, transition to more severe forms was seen in 44.2%, resulting in comparable distribution among severity patterns at last follow-up (mild 28.4%, moderate 33.1%, severe 38.5%). Neuropsychiatric involvement at onset (OR 6.33, 95% CI 1.22 to 32.67), male sex (OR 4.53, 95% CI 1.23 to 16.60) and longer disease duration (OR 1.09 per 1 year, 95% CI 1.04 to 1.14) were independently associated with transition from mild or moderate to severe disease. Patients with disease duration ≥3 years who progressed to more severe disease had more than 20-fold increased risk to accrue irreversible damage. CONCLUSION: Almost half of patients with initially non-severe disease progress to more severe forms of SLE, especially men and patients with positive anti-double-stranded DNA or neuropsychiatric involvement at onset. These data may have implications for the management of milder forms of lupus. |
format | Online Article Text |
id | pubmed-7326262 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-73262622020-07-02 Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease Nikolopoulos, Dionysis S Kostopoulou, Myrto Pieta, Antigoni Flouda, Sofia Chavatza, Katerina Banos, Aggelos Boletis, John Katsimbri, Pelagia Boumpas, Dimitrios T Fanouriakis, Antonis Lupus Sci Med Epidemiology and Outcomes OBJECTIVE: Changes in the care of patients with SLE dictate a re-evaluation of its natural history and risk factors for disease deterioration and damage accrual. We sought to decipher factors predictive of a deterioration in phenotype (‘transition’) in patients initially presenting with non-severe disease. METHODS: Patients from the ‘Attikon’ cohort with disease duration ≥1 year were included. Disease at diagnosis was categorised as mild, moderate or severe, based on the British Isles Lupus Assessment Group manifestations and physician judgement. ‘Transition’ in severity was defined as an increase in category of severity at any time from diagnosis to last follow-up. Multivariable logistic regression was performed to identify baseline factors associated with this transition. RESULTS: 462 patients were followed for a median (IQR) of 36 (120) months. At diagnosis, more than half (56.5%) had a mild phenotype. During disease course, transition to more severe forms was seen in 44.2%, resulting in comparable distribution among severity patterns at last follow-up (mild 28.4%, moderate 33.1%, severe 38.5%). Neuropsychiatric involvement at onset (OR 6.33, 95% CI 1.22 to 32.67), male sex (OR 4.53, 95% CI 1.23 to 16.60) and longer disease duration (OR 1.09 per 1 year, 95% CI 1.04 to 1.14) were independently associated with transition from mild or moderate to severe disease. Patients with disease duration ≥3 years who progressed to more severe disease had more than 20-fold increased risk to accrue irreversible damage. CONCLUSION: Almost half of patients with initially non-severe disease progress to more severe forms of SLE, especially men and patients with positive anti-double-stranded DNA or neuropsychiatric involvement at onset. These data may have implications for the management of milder forms of lupus. BMJ Publishing Group 2020-06-29 /pmc/articles/PMC7326262/ /pubmed/32601172 http://dx.doi.org/10.1136/lupus-2020-000394 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Epidemiology and Outcomes Nikolopoulos, Dionysis S Kostopoulou, Myrto Pieta, Antigoni Flouda, Sofia Chavatza, Katerina Banos, Aggelos Boletis, John Katsimbri, Pelagia Boumpas, Dimitrios T Fanouriakis, Antonis Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title | Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title_full | Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title_fullStr | Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title_full_unstemmed | Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title_short | Transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
title_sort | transition to severe phenotype in systemic lupus erythematosus initially presenting with non-severe disease: implications for the management of early disease |
topic | Epidemiology and Outcomes |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7326262/ https://www.ncbi.nlm.nih.gov/pubmed/32601172 http://dx.doi.org/10.1136/lupus-2020-000394 |
work_keys_str_mv | AT nikolopoulosdionysiss transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT kostopouloumyrto transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT pietaantigoni transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT floudasofia transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT chavatzakaterina transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT banosaggelos transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT boletisjohn transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT katsimbripelagia transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT boumpasdimitriost transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease AT fanouriakisantonis transitiontoseverephenotypeinsystemiclupuserythematosusinitiallypresentingwithnonseverediseaseimplicationsforthemanagementofearlydisease |